Dr. Christopher M. Davis, DO
Family Medicine (Family Medicine Physician)
525 Verdae Blvd Ste 200
Greenville, SC 29607
Who else practices at this address →
Greenville County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Edward Via Col of Osteo Medicine-Carolinas Campus (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 39
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: Edward Via Col of Osteo Medicine-Carolinas Campus
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
SC license 41050
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Spartanburg Medical Center Spartanburg, SC
- Pelham Medical Center Greer, SC
Medical groups
- Musc Affiliate Physicians (48 clinicians)
- Westgate Family Physicians PA (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 39
- Services billed
- 536
- Patients’ average age
- 72
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 19 payments worth $321 in total to this clinician.
| Novo Nordisk Inc | $123 |
|---|---|
| AbbVie Inc. | $95.48 |
| Pfizer Inc. | $30.90 |
| Tris Pharma Inc | $24.44 |
| Axsome Therapeutics, Inc. | $19.07 |
| AstraZeneca Pharmaceuticals LP | $14.58 |
| Amgen Inc. | $13.61 |
| Food and Beverage | $321 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 7 companies. The companies reported $664,275 in research payments for these studies, mostly to the institutions running them.
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Eli Lilly and Company · Completed · NCT05929066 - ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP)
Abbott Laboratories - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Amgen Inc. - A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06299098 - A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly and Company · Completed · NCT05929079 - A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly and Company · Completed · NCT05882045 - Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Sanofi Pasteur Inc. · Active, not recruiting · NCT06824194 - A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compa…
Merck Sharp & Dohme LLC - A phase 3 randomized doubleblind placebocontrolled study to evaluate the efficacy and safety of rimegepant in migraine prevention in children and adolescents 6 to 18 years of age
Pfizer Inc. - A phase 4 randomized doubleblind placebocontrolled study to evaluate the efficacy and safety of rimegepant in episodic migraine prevention with multiple dosing regimens
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.